Krystal Biotech, Inc. - שווי פירמה כולל KRYS

Krystal Biotech, Inc. (KRYS) operates its own ANCOR sterile manufacturing facility in the US, ensuring flawless quality in the production of biologics. The business relies on its status as a defensive asset, as demand for gene therapy for rare skin pathologies remains unaffected by economic crises. The market dynamics of the asset with the 8769.52 indicator reflect the market valuation of the company, whose current success is tied to the commercialization of Vyjuvek and the approval of insurance reimbursements.

Enterprise Value represents the total buyout price of a business, combining market capitalization and net debt to determine the actual cost of acquiring an asset. For Krystal Biotech, Inc. (KRYS), which attracts elite geneticists through generous funding, the current enterprise value reflects the balance between capital investments in innovation and debt load, serving as an indicator of the company's overvaluation.